eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
NOWOŚĆ
Portal dla gastroenterologów!
www.egastroenterologia.pl
SCImago Journal & Country Rank
2/2024
vol. 19
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł oryginalny

Vonoprazan a novel potassium competitive acid blocker; another leap forward

Maha Elsabaawy
1
,
Ahmed Shaban
1
,
Ahmed Ezz Al-Arab
2
,
Osama Elbahr
1
,
Ahmed Edrees
1
,
Sameh Afify
1

  1. Depatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El‑Koum, Menoufia, Egypt
  2. Depatment of internal Medicine, Faculty of Medicine, Menoufia University, Shebeen El‑Koum, Menoufia, Egypt
Gastroenterology Rev 2024; 19 (2): 135–142
Data publikacji online: 2024/05/08
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Introduction
The eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H. pylori eradication.

Aim
to study the efficacy and safety of vonoprazan as a component of first-line H. pylori eradication treatment compared with conventional PPI-based therapy.

Material and methods
This randomised (one to one) non-blinded study was conducted on 400 consecutive proven H. pylori infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.

Results
The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (p = 0.004). There was no significant difference regarding adverse events between both patient groups.

Conclusions
Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line H. pylori eradication treatment. Vonoprazan was generally safe and well tolerated.

© 2024 Termedia Sp. z o.o.
Developed by Bentus.